Royalty Pharma
RPRX
RPRX
485 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 205 increasing their positions, 131 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
7% more funds holding
Funds holding: 453 → 485 (+32)
5.35% less ownership
Funds ownership: 81.19% → 75.84% (-5.4%)
6% less capital invested
Capital invested by funds: $12.3B → $11.6B (-$769M)
Holders
485
Holding in Top 10
10
Calls
$50.3M
Puts
$9.31M
Top Buyers
| 1 | +$216M | |
| 2 | +$193M | |
| 3 | +$86.6M | |
| 4 |
DAM
Dorsey Asset Management
Chicago,
Illinois
|
+$85.1M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$79.1M |
Top Sellers
| 1 | -$921M | |
| 2 | -$448M | |
| 3 | -$93.6M | |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$89M |
| 5 |
Morgan Stanley
New York
|
-$88.3M |
